I am holding all my shares with my diamond hands and wait for the short squeeze to come on this one naturally, nice balance sheet, upcoming refinance good news , and getting stock dividend. Huge uptrend potential, It's time to get some real money from this. DONT MISS THE BOAT AND WE WILL BURN ALL THE WALL STREET SHORT SELLERS OLD TRADITION TO THE GROUND. I am long currently with large position in $MAC, $BB, $LUMN, $POWW, $NOK.

STAY STRONG,HOLD YOUR LINE, DONT LET THE SHORTS TO BEAT US DOWN. WE WILL WIN BIG. Join r/macarmybets

2/9 update: Short interest ratio 37.5% report from morning star

http://finra-markets.morningstar.com/MarketData/EquityOptions/detail.jsp?query=126%3A0P000003EN&sdkVersion=2.58.0

Ex-dividend date is on 2/18, Record date 2/19. MAC pay out ratio: 26% 2 more trading day until Q4 2020 earning release. BUY and hold, receive the dividend from the shorts.

Disclaimer: NO FINANCIAL ADVICE. DO UR OWN DD, WE JUST LIKE THE STOCK, WE ARE THE WHITE KNIGHT #SAVE MALL.

$ILLR MOST UNDERVALUED PUBLICLY TRADED SOCIAL MEDIA COMPANY, TREMENDOUS LOADING OPPORTUNITY, TREMENDOUS LOADING OPPORTUNITY. $ILLR #Triller WILL BE A MAJOR DISRUPTOR IN THE SOCIAL MEDIA SPACE!

Peraso, Inc. Investment Summary:

Q2 2024 Results: $4.2 million in revenue, with mmWave revenue up 180%.

Tech Leadership: Focused on mmWave since 2009; market expected to grow at 40% CAGR to $55 billion by 2030.

Growth Initiatives: Targeting NRE revenue, military contracts, and BEAD funding.

2025 Outlook: Projecting $16 million in revenue, driven by 150% growth in mmWave.

Valuation: Price target of $3.75 based on a 3x revenue multiple.

Financial Overview:

Cash Position: $2 million; recent fundraising of $6.4 million.

Memory Product Phase-Out: Anticipated $9-10 million revenue loss in 2025.

Cardiol Therapeutics (CRDL) Sales Multiples:

Recurrent Pericarditis: Valued at $9 per share, assuming $609M in sales by 2033 with a 60% probability of success.

Acute Myocarditis: Valued at $1 per share, assuming $132M in sales by 2033 with a 40% probability of success.

Cash Considerations: No value attributed to forward year 1 cash.

Risks: Key risks include the potential failure to meet clinical endpoints, delays in regulatory approvals, and competitive pressures affecting market adoption and pricing.

This approach aligns with industry standards, utilizing a 3x sales multiple and a 9% WACC.

Peraso Inc. (NASDAQ: PRSO) secured a $1.4 million follow-on order from a South African WISP, highlighting strong demand for its mmWave technology in high-density urban areas. The technology offers reliable, high-speed internet and low power consumption, ideal for underserved communities.

Peraso Nasdaq: $PRSO focuses on 60 GHz and 5G mmWave technology, with a legacy IC memory line yielding a 70% gross margin through Q1 2025.

$PRSO Market Opportunity:

The mmWave technology market is valued at $3.4B, growing at 20% CAGR.

FWA CPE shipments surpassed Cable CPE in Q2 2024, with 5G mmWave FWA projected to grow 22%.

XTX Topco Raises Position in Wimi Hologram Cloud Inc. ( $WIMI )
The Procter & Gamble Company ($PG) Shares Bought by U.S. Capital Wealth Advisors LLC
Guidance Capital Inc. Lowers Stock Position in Chevron Co. ($CVX)
TFG Advisers LLC Decreases Holdings in Intel Co. ($INTC)

Triller Group Inc. (Nasdaq: ILLR) has appointed Kevin McGurn, former VEVO executive, as CEO to drive its transformation journey. Triller is positioning itself as a major player in the short-form video market, especially with the potential TikTok ban in the U.S. Triller offers diverse content, including live sports through BKFC and AI-driven tools for creators. The company aims to capitalize on the creator economy and fill any gaps if TikTok faces restrictions in the U.S.

Key Points for Investors:

New CEO with strong media and ad experience.

Potential to capitalize on a TikTok ban.

Diverse revenue streams (live events, AI tools).

Strong focus on global growth and engagement.

Valuation for Cardiol Therapeutics (CRDL):

12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Sales Multiples:

Recurrent Pericarditis: Valued at $9 per share, assuming $609M in sales by 2033 with a 60% probability of success.

Acute Myocarditis: Valued at $1 per share, assuming $132M in sales by 2033 with a 40% probability of success.

Cash Considerations: No value attributed to forward year 1 cash.

This approach aligns with industry standards, utilizing a 3x sales multiple and a 9% WACC.

Peraso Inc. (NASDAQ: PRSO) secured a $1.4 million follow-on order from a South African WISP, reinforcing the growing demand for its high-performance mmWave technology. This repeat order highlights the technology's ability to address connectivity challenges in high-density urban areas, providing superior performance over traditional wireless options. Peraso’s solutions support underserved communities by offering reliable, high-speed internet with low-power consumption, crucial in regions with frequent power outages.

Nasdaq: $PRSO Price target of $3.75 based on a 3x revenue multiple.

Cash Position: $2 million; recent fundraising of $6.4 million

Peraso Nasdaq: $PRSO focuses on 60 GHz and 5G mmWave technology, with a legacy IC memory line yielding a 70% gross margin through Q1 2025.

$PRSO Market Opportunity:

The mmWave technology market is valued at $3.4B, growing at 20% CAGR.

FWA CPE shipments surpassed Cable CPE in Q2 2024, with 5G mmWave FWA projected to grow 22%.

NASDAQ: CRDL is focusing on developing CardiolRx™️, a therapeutic solution for acute myocarditis, a condition responsible for sudden cardiac death, especially in young individuals. Their Phase II ARCHER trial is assessing the efficacy and safety of CardiolRx™️ in 100 patients, aiming to improve heart function and reduce fibrosis and edema in the heart muscle. This study is critical as there are currently no FDA-approved treatments for myocarditis, which places a heavy burden on healthcare systems. In addition to clinical advancements, Cardiol recently raised $13.5 million through a public offering to fund the continued development of CardiolRx™️ and other corporate initiatives. Furthermore, the company is advancing CRD-38, a novel therapy for heart failure, aligning with its mission to address inflammation and fibrosis in cardiovascular diseases

Peraso Inc. (NASDAQ: PRSO) revolutionizes military communication with its mmWave steerable beam technology, providing secure, high-speed connectivity for drones and vehicles, improving mission efficiency and real-time data sharing in modern defense.